Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00174772
Status:
COMPLETED
Last Update Posted:
2010-02-17
First Post:
2005-09-12
Brief Title:
Pulmonart Docetaxel - Non-Small Cell Lung Cancer NSCLC
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
A Two Arm Phase II Study Comparing DocetaxelCisplatin Induction Therapy Followed By Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Followed By Consolidation DocetaxelCisplatin in Patients With Locally Advanced Unresectable NSCLC Stage IIIA-Multiple cN2 or IIIB
Status:
COMPLETED
Status Verified Date:
2010-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primary Objective
To evaluate the toxicitysafety profile of docetaxelcisplatin induction therapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by consolidation docetaxelcisplatin in patients with locally advanced unresectable NSCLC stage IIIA- multiple cN2 or IIIB
Secondary Objective
To estimate efficacy parameters in overall response rate progression free survival and 1 year survival for each of the two above mentioned arms
To evaluate the toxicitysafety profile of docetaxelcisplatin induction therapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by consolidation docetaxelcisplatin in patients with locally advanced unresectable NSCLC stage IIIA- multiple cN2 or IIIB
Secondary Objective
To estimate efficacy parameters in overall response rate progression free survival and 1 year survival for each of the two above mentioned arms
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None